“ 2023 marked by Ceapro's achievement of key milestones and progress toward its next phase of growth “ R&D activities focused on advancement of avenanthramide Phase 1-2a clinical study and...
Aeterna Zentaris & Ceapro Merger Approved by Securityholders at Special Meetings
EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (œCeapro or the œCompany), today provided an update on its progress across its current business. On...
EDMONTON, Alberta, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (Ceapro or the Company) is pleased to announce that it has mailed and filed a management information...
TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (Aeterna) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (Ceapro), two innovative...
“ Study being led by Dr. Jean-Claude Tardif at the Montreal Heart Institute “ No adverse reactions observed, and study can continue as planned EDMONTON, Alberta, Dec. 13, 2023 (GLOBE NEWSWIRE) --...
Product development focused on the production of powder formulations of oat beta glucan and avenanthramides for cosmeceuticals market Technology development focused on the PGX pilot scale...
Study being led by Dr. Jean-Claude Tardif at the Montreal Heart Institute Screening of healthy subjects is now underway Phase 1-2a study to provide valuable insights into the safety and...
PGX processing unit with a 10X (100 L) vessel capacity to be installed and tested at NATEX pilot testing facility in AustriaYeast beta glucan (YBG) to be the first bio active to be processed at this...
- $5.5 million first six-month 2023 sales vs. $11.7 million for the same period in 2022; sales lagging by one quarter due to stocking campaign by one major customer in 2022 and further Marketplace...